-  INCLUSION CRITERIA:

        Inclusion Criteria - Recipient

          -  Patients must have a histologically or cytologically confirmed hematologic malignancy
             with standard indication for allogeneic hematopoietic cell transplantation limited to
             one of the following:

               -  Acute myeloid leukemia (AML) of intermediate or adverse risk disease by the 2017
                  European LeukemiaNet criteria in first morphologic complete remission (<5% blasts
                  in the bone marrow, no detectable abnormal peripheral blasts, and no
                  extramedullary disease)

               -  AML of any risk in second or subsequent morphologic complete remission

               -  B-cell acute lymphoblastic leukemia in first or subsequent complete remission

               -  T-cell acute lymphoblastic leukemia with minimal residual disease detected after
                  first line therapy and/or adverse genetics (no NOTCH1/FBXW7 mutation or presence
                  of N/K-RAS mutation and/or PTEN gene alteration)

               -  Myelodysplastic syndrome of intermediate or higher score by the Revised
                  International Prognostic Scoring System (IPSS-R)

               -  Primary myelofibrosis of intermediate-2 or higher risk by the DIPSS

               -  Chronic myelomonocytic leukemia

               -  Chronic myelogenous leukemia resistant to or intolerant of greater than or equal
                  to 3 tyrosine kinase inhibitors or with history of accelerated phase or blast
                  crisis

               -  B-cell lymphoma including Hodgkin lymphoma that has relapsed within 1 year of
                  completion of primary treatment

               -  Chronic lymphocytic leukemia with 17p deletion and/or unmutated IgHV or
                  refractory to or intolerant of both BTK and PI3K inhibitors

               -  Mature T or NK neoplasms as defined in the WHO guidelines of sufficient type and
                  severity for allogeneic HCT based on the Prognostic Index for T-cell lymphoma
                  (PIT) score of low-intermediate risk or higher or on recently published clinical
                  practice guidelines

               -  Hematologic malignancy of dendritic cell or histiocytic cell type

               -  Multiple myeloma, stage III, relapsing after therapy with both a proteasome
                  inhibitor and an immunomodulatory drug (IMiD)

          -  Age 15-65. Patients <18 years old must be at least 50 kg. Note: Because patients 15-17
             years old and <50 kg are not able to be cared for on the adult oncology wards and by
             the investigative team, they are excluded.

          -  At least one potentially suitable HLA-haploidentical donor.

          -  Karnofsky performance score greater than or equal to 60

          -  Adequate organ function defined as possessing all of the following:

               -  Cardiac ejection fraction greater than or equal to 45% by 2D ECHO;

               -  Forced expiratory volume-1 (FEV-1), forced vital capacity (FVC), and diffusing
                  capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) all of
                  greater than or equal to 50% predicted;

               -  Estimated serum creatinine clearance of greater than or equal to 60
                  ml/minute/1.73m(2) calculated using eGRF in the clinical lab for adults and the
                  Schwartz formula for pediatric subjects;

               -  Total bilirubin less than or equal to 2X the upper limit of normal;

               -  Alanine aminostransferase and aspartate aminotransferase less than or equal to 3X
                  the upper limit of normal.

          -  Myeloablative conditioning is toxic to the developing human fetus and is teratogenic.
             For this reason, the following measures apply:

               -  Women of child-bearing potential (WOCBP) and men must agree to use adequate
                  contraception (hormonal or barrier method of birth control; abstinence) prior to
                  study entry and for at least one year post-transplant.

               -  Should a woman become pregnant or suspect she is pregnant while she or her
                  partner is participating in this study, she should inform her treating physician
                  immediately.

               -  WOCBP must have a negative serum or urine pregnancy test within 7 days prior to
                  enrollment.

          -  Ability of subject or Legally Authorized Representative to understand and the
             willingness to sign a written informed consent document. Pediatric patients (<18 years
             of age) will provide assent, and the parent(s) or legal guardian(s) will provide
             informed consent.

          -  Subjects requiring standard therapies to prepare for HCT should be referred in
             remission if possible. However, these diseases are often aggressive and require swift
             evaluation for HCT while concurrently attempting to establish disease control through
             the administration of standard therapies. If ongoing therapy for the underlying
             disease outside of the NIH is not in the best interest of the subject according to the
             clinical judgment of the PI, then the subject may receive up to 2 cycles of standard
             treatment for his/her underlying hematologic malignancy as a bridge to HCT on this
             protocol, prior to starting the research phase of the study. The subject must have a
             Karnofsky performance status of greater than or equal to 60% at the start of the first
             cycle to proceed. If it becomes apparent that the subject will not be able to proceed
             to HCT, then he/she must come off study. Subjects receiving standard therapy will be
             told about the therapy, associated risks, potential benefits, alternatives to the
             proposed therapy, and the availability of receiving the same treatment elsewhere,
             outside of a research protocol.

        Inclusion Criteria - Related Donor

          -  Related donor deemed suitable and eligible, and willing to donate, per clinical
             evaluations, who are additionally willing to donate blood, bone marrow, saliva, oral
             swab and stool for research. Related donors will be evaluated in accordance with
             existing institutional Standard Policies and Procedures for determination of
             eligibility and suitability for clinical donation

          -  Age greater than or equal to 12 years

        EXCLUSION CRITERIA:

        Exclusion Criteria - Recipient

          -  Patients who are receiving any other investigational agents. Prior experimental
             therapies must have been completed at least 4 weeks prior to the date of beginning
             conditioning.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection excluding controlled fungal infection on appropriate treatment, symptomatic
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, endocrinopathy
             (significant uncontrolled or untreated hypothyroidism, hyperthyroidism, or adrenal
             insufficiency), or active psychiatric illness/social situations that would limit
             compliance with study requirements

          -  Prior myeloablative conditioning for autologous or allogeneic HCT.

          -  An HLA-matched-sibling donor who is available and willing to donate bone marrow. Note:
             The patient must have access to HCT using this donor for this to be an exclusion
             criterion.

          -  Pregnant women or women who intend to become pregnant during the study are excluded
             because myeloablative conditioning is toxic to the developing fetus with the potential
             for teratogenic or abortifacient effects.

          -  The potential for some of the study medications to be transmissible via breast milk of
             nursing mothers is unknown. Because there is unknown but potential risk for adverse
             events in nursing infants secondary to treatment of the mother, breastfeeding must be
             discontinued.

          -  Active malignancy of non-hematopoietic type (excluding non-melanoma skin cancers)
             which is: metastatic, or relapsed/refractory to treatment, or locally advanced and not
             amenable to curative treatment, or limited disease treated with curative intent
             treatment within the last 2 years. This excludes non-melanoma skin cancers.

          -  The severity of the hematologic malignancy does not warrant the potential toxicity of
             myeloablative allogeneic HCT as judged by the PI.

        Exclusion Criteria - Related Donor

        -None